<DOC>
	<DOCNO>NCT01824342</DOCNO>
	<brief_summary>This multi-national , multi-center , open-label , single-arm extension study prolongation bone metastasis-free survival men hormone-refractory ( androgen independent ) prostate cancer . Patients currently participate phase 3 study 20050147 ( NCT00286091 ) offer study positive benefit : risk compare placebo determine 20050147 study . The primary endpoint 20050147 study bone metastases-free survival determine time first occurrence bone metastases ( either symptomatic asymptomatic ) death cause . Participants receive open-label denosumab administer every 4 week ( Q4W ) subcutaneously ( SC ) develop bone metastasis 3 year , whichever come first .</brief_summary>
	<brief_title>Denosumab Prolonging Bone Metastasis-Free Survival Men With Hormone-Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Subjects currently undergo every 4 week schedule assessment phase 3 study 20050147 Subjects must sign informed consent study specific procedure perform Developed sensitivity mammalian cell derive drug product 20050147 study Currently receive unapproved investigational product denosumab Any disorder , opinion investigator , may compromise ability subject give write informed consent and/or comply study procedure</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>